妈富隆治疗围绝经期功能失调性子宫出血临床疗效及其对性激素影响的观察  

Observation of clinical effect by Marvelon in the treatment of perimenopausal dysfunctional uterine bleeding and its influence on sex hormone

作　　者：黎春梅 江雪芳[2] 

机构地区：[1]广东省清远市妇幼保健院妇产科,511510 [2]广东省妇幼保健院妇科

出　　处：《中国现代药物应用》2016年第11期3-5,共3页Chinese Journal of Modern Drug Application

摘　　要：目的了解去氧孕烯炔雌醇(妈富隆)治疗围绝经期功能失调性子宫出血(围绝经期功血)的临床疗效及其对血清性激素浓度的影响。方法 130例围绝经期功血患者,随机分为米非司酮组与妈富隆组,各65例。米非司酮组:诊刮术后5 d口服米非司酮;妈富隆组:诊刮术后5 d口服妈富隆。记录两组控制出血时间和完全止血时间;观察两组临床疗效及不良反应;治疗前后放射免疫法测定患者促卵泡生成素(FSH)、黄体生成素(LH)、雌二醇(E2)的浓度;B超检查子宫内膜厚度;病理检查子宫内膜病理改变。结果米非司酮组控制出血、完全止血时间长于妈富隆组(P<0.05);妈富隆组临床治疗总有效率优于米非司酮组(P<0.05);妈富隆组治疗后FSH、LH浓度下降,与治疗前和米非司酮组治疗后比较差异均有统计学意义(P<0.05);妈富隆组治疗后子宫内膜厚度低于米非司酮组(P<0.05);两组治疗后病理结果比较差异有统计学意义(P<0.05)。结论妈富隆治疗围绝经期功血优于米非司酮,能够抑制血清FSH的释放,使内源性LH下降,有效抑制子宫内膜增生,临床疗效显著,安全可靠,值得推广。Objective To understand clinical effect by desogestrel and ethinylestradiol（Marvelon） in the treatment of perimenopausal dysfunctional uterine bleeding and its influence on serum sex hormone. Methods A total of 130 patients with perimenopausal dysfunctional uterine bleeding were randomly divided into mifepristone group and Marvelon group, with 65 cases in each group. The mifepristone group received oral administration of mifepristone in 5 d after diagnostic curettage, and the Marvelon group received oral administration of Marvelon instead. Records were made on control bleeding time and complete hemostasis time, and observation was made on clinical effects and adverse reactions of the two groups. Radioimmunoassay was applied to detect folliclestimulating hormone（FSH）, luteinizing hormone（LH） and estradiol（E2） concentrations. Endometrial thickness was detected by B ultrasound, and endometrial pathological changes were taken into pathological examination. Results The mifepristone group had longer control bleeding time and complete hemostasis time than the Marvelon group（P0.05）, while the Marvelon group had better total effective rate than the mifepristone group（P0.05）. After treatment, the Marvelon group had reduced FSH and LH concentrations, and its differences withthose before treatment and those in the mifepristone group after treatment all had statistical significance（P0.05）. The Marvelon group had lower endometrial thickness after treatment than the mifepristone group（P0.05）. The difference of pathological result between the two groups had statistical significance after treatment（P0.05）. Conclusion Marvelon provides better effect than mifepristone in treating perimenopausal dysfunctional uterine bleeding. It can effectively restrain endometrial hyperplasia with remarkable effect and high safety, and it is worth promoting.

关 键 词：去氧孕烯炔雌醇 米非司酮 围绝经期 功能失调性子宫出血 性激素 

分 类 号：R711.52[医药卫生—妇产科学]